Showing 1 - 5 results of 5 for search 'Yuko Ishihara', query time: 0.03s Refine Results
  1. 1
    PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES

    PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED AS... by Mitsuhito Hirano, Kikuaki Yoshida, Kei Hirano, Yukako Teramoto, Mikako Tamba, Nobuhiko Yamauchi, Yuko Shirouchi, Yuko Ishihara, Hiroaki Asai, Yuko Mishima, Kengo Takeuchi, Dai Maruyama

    Published 2023-08-01
    Get full text
    Article
  2. 2
    Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

    Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following... by Yuko Shirouchi, Noriko Nishimura, Yuko Mishima, Yuko Ishihara, Hiroaki Asai, Mikako Tamba, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Kengo Takeuchi, Takashi Terauchi, Dai Maruyama

    Published 2023-08-01
    Get full text
    Article
  3. 3
    P1106: CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY.

    P1106: CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL S... by Kei Hirano, Kikuaki Yoshida, Norihito Inoue, Naoko Tsuyama, Yukako Teramoto, Mitsuhito Hirano, Mikako Tanba, Nobuhiko Yamauchi, Yuko Shirouchi, Yuko Ishihara, Hiroaki Asai, Yuko Mishima, Senzo Taguchi, Toshiaki Hirasawa, Kengo Takeuchi, Dai Maruyama

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.

    Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides. by Kana Sakamoto, Hideki Nakasone, Hidenori Wada, Ryoko Yamasaki, Yuko Ishihara, Koji Kawamura, Masahiro Ashizawa, Miki Sato, Kiriko Terasako-Saito, Tomohito Machishima, Shun-ichi Kimura, Misato Kikuchi, Shinichi Kako, Junya Kanda, Rie Yamazaki, Aki Tanihara, Junji Nishida, Yoshinobu Kanda

    Published 2013-01-01
    Get full text
    Article
  5. 5
    Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation

    Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation by Chihiro Yamamoto, Hirotomo Nakashima, Takashi Ikeda, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Takashi Nagayama, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Miyuki Sugimoto, Yuko Ishihara, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Shin-ichiro Fujiwara, Masuzu Ueda, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda

    Published 2019-11-01
    Get full text
    Article

Search Tools: